Market Overview

Tactile Systems' Valuation Is 'Getting Stretched,' BTIG Says In Downgrade

Share:
Tactile Systems' Valuation Is 'Getting Stretched,' BTIG Says In Downgrade
Related
The Daily Biotech Pulse: Advaxis Posts Narrower Loss, Endocyte Announces $175M Offering, Leadership Transition At Insulet
77 Biggest Movers From Yesterday

After doubling in value over the past seven months alone, shares of Tactile Systems Technology Inc (NASDAQ: TCMD) are trading at a "stretched" valuation despite expectations for continued growth ahead, according to BTIG.

The Analyst

BTIG's Sean Lavin downgraded Tactile Systems Technology from Buy to Neutral with no assigned price target.

The Thesis

Tactile Systems, a medical technology company that focuses on treatment of chronic diseases at home, should be able to exceed its own 2018 sales guidance growth of 21-23 percent, Lavin said in the Monday downgrade note. Investors should expect the company to deliver future earnings beats, but given the company's momentum, this is already mostly "expected" at the stock's current price, the analyst said. 

Three concerns exist with Tactile Systems, Lavin said:

  • The lack of intellectual property protection on key patents including Flexitouch is "not ideal."
  • Pneumatic compression device companies face minimal barriers to entry given the relatively low tech involved.
  • A mid-single digit price erosion is expected and is higher than other medical technology peers.

Nevertheless, the company's fundamentals remains as strong today as it in the past, and the analyst's downgrade from a bullish stance is strictly due to valuation concerns, he said. The entire medical technology sector is trading above historical multiples, so investors may want to consider a "disciplined" approach to Tactile Systems' stock, according to BTIG. 

Price Action

Shares of Tactile Systems Technology were plunging more than 8 percent off the open Monday. 

Related Links:

Inspire Medical Systems Goes Public

JPMorgan Diagnoses The MedTech Space: Stock Picks And Pans

Latest Ratings for TCMD

DateFirmActionFromTo
Sep 2018Canaccord GenuityMaintainsBuyBuy
Jun 2018Canaccord GenuityMaintainsBuyBuy
Jun 2018Northland SecuritiesDowngradesMarket PerformUnderperform

View More Analyst Ratings for TCMD
View the Latest Analyst Ratings

Posted-In: btig Flexitouch Medical TechnologyAnalyst Color Downgrades Health Care Analyst Ratings General Best of Benzinga

 

Related Articles (TCMD)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
MOSJP MorganDowngrades33.0
BACKeefe Bruyette & WoodsDowngrades29.0
TVPTImperial CapitalDowngrades15.8
ACORGoldman SachsDowngrades10.0
APTIJefferiesDowngrades38.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

AXA Equitable's Valuation Doesn't Reflect Its Solid Fundamentals, Morgan Stanley Says In Positive Initiation

Stifel Books A Long-Term Stay In Wyndham Hotels After Spinoff